<![CDATA[European Commission Approves Tovorafenib in BRAF+ Pediatric Low-Grade Glioma]]>

Summary: The European Commission just approved a new medicine called tovorafenib (Ojemda) for kids and young adults with a specific type of brain tumor. This tumor is called a low-grade glioma with a "BRAF" change. The medicine is for kids 6 months and older who have already tried at least one other treatment.

In a big study called FIREFLY-1, this new drug helped shrink or control the tumors in more than half of the patients. It is easy to take because it comes as a pill or a liquid. While it does have some side effects—like tiredness, upset stomach, and surprisingly, changes in hair color—most were easy to manage. Doctors say this new targeted therapy gives families a lot of hope after years of tough choices.

Source: cancernetwork URL: cancernetwork.com/view/european-commission-approves-tovorafenib-in-braf-pediatric-low-grade-glioma (opens in new tab)